HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ilaria Barbazza Selected Research

tanimilast

10/2022The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.
4/2022The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
1/2021The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ilaria Barbazza Research Topics

Disease

3Chronic Obstructive Pulmonary Disease (COPD)
10/2022 - 01/2021
1Lung Diseases (Lung Disease)
04/2022
1Inflammation (Inflammations)
04/2022
1COVID-19
01/2021
1Atopic Dermatitis (Atopic Eczema)
01/2021
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2021
1Neoplasms (Cancer)
05/2020

Drug/Important Bio-Agent (IBA)

3tanimilastIBA
10/2022 - 01/2021
3Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
10/2022 - 01/2021
2Phosphodiesterase 4 InhibitorsIBA
04/2022 - 01/2021
1Bronchodilator Agents (Bronchodilators)IBA
10/2022
1GlucocorticoidsIBA
10/2022
1Immunomodulating AgentsIBA
01/2021
1Neoplasm Antigens (Tumor Antigens)IBA
05/2020